We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

Fund managers haven’t disclosed any holdings of LENZ yet.

LENZ Hedge Fund Activity: Q1 2026 in Review

145 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q1 2026, worth a combined $303M — down 46% from $562M a quarter earlier.

Sellers outnumbered buyers: 47 funds closed out of LENZ and 36 opened new positions — a net loss of 11 holders — while 28 trimmed existing stakes and 56 added.

The largest buyer was Squarepoint, adding an estimated $14.3M. The largest seller was UBS Group, cutting an estimated $19.9M.

  • 145 institutional investors held LENZ Therapeutics (LENZ) as of Q1 2026, down from 160 in Q4 2025.
  • Funds reported $303M of LENZ Therapeutics stock for Q1 2026, down 46% quarter-over-quarter.
  • 36 funds opened new LENZ Therapeutics positions in Q1 2026 and 47 closed out, a net change of -11 holders.
  • The largest LENZ Therapeutics buyer in Q1 2026 was Squarepoint, an estimated $14.3M added.
  • The largest LENZ Therapeutics seller in Q1 2026 was UBS Group, an estimated $19.9M sold.

Based on aggregated 13F filings for Q1 2026.